Pfizer Inc. $PFE Position Cut by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 9.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 3,803,506 shares of the biopharmaceutical company’s stock after selling 380,452 shares during the period. Commonwealth Equity Services LLC owned 0.07% of Pfizer worth $96,913,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Pfizer in the second quarter valued at approximately $2,270,157,000. Vanguard Group Inc. grew its holdings in Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Pfizer by 43.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after acquiring an additional 5,662,309 shares during the period. Assenagon Asset Management S.A. raised its stake in Pfizer by 75.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after acquiring an additional 3,722,531 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Pfizer by 84.9% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after acquiring an additional 3,472,240 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.18 on Tuesday. The company has a market capitalization of $143.14 billion, a PE ratio of 14.64 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a fifty day moving average of $25.19 and a 200-day moving average of $24.93. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.